Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Bone cancer in 2011

Prevention and treatment of bone metastases

Bone-targeting treatments have transformed the quality of life of patients with metastatic bone disease. 2011 saw the emergence of denosumab—a RANK ligand-specific antibody—as a more-effective alternative treatment to bisphosphonates and of data on the use of bone-targeting treatments to prevent metastasis from breast and prostate cancers.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Stopeck, A. T. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132–5139 (2010).

    Article  CAS  Google Scholar 

  2. Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813–822 (2011).

    Article  CAS  Google Scholar 

  3. Henry, D. H. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125–1132 (2011).

    Article  CAS  Google Scholar 

  4. Saad, F. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol. http://dx.doi.org/10.1093/annonc/mdr435.

  5. Parker, C. et al. Overall survival benefit of radium-223 chloride (alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomised trial (ALSYMPCA) [abstract]. Eur. J. Cancer 47 (Suppl. 2), a3 (2011).

    Article  Google Scholar 

  6. Gnant, M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679–691 (2009).

    Article  CAS  Google Scholar 

  7. Gnant, M. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 12, 631–641 (2011).

    Article  CAS  Google Scholar 

  8. Gnant, M. et al. Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12 [abstract]. J. Clin. Oncol. 29 (Suppl. 15), a520 (2011).

    Article  Google Scholar 

  9. Coleman, R. E. et al. Breast-cancer adjuvant therapy with and without zoledronic acid. N. Engl. J. Med. 365, 1396–1405 (2011).

    Article  CAS  Google Scholar 

  10. Smith, M. R. et al. Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: results of a global phase 3, randomised, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(11)61226-9.

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

R. E. Coleman declares that he has received honoraria from Amgen and Novartis. He has also received a research grant from and was on the advisory board of Novartis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coleman, R. Prevention and treatment of bone metastases. Nat Rev Clin Oncol 9, 76–78 (2012). https://doi.org/10.1038/nrclinonc.2011.198

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2011.198

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer